Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

SCRI Development Innovations

Status and phase

Completed

Phase 2

Conditions

Lung Cancer

Treatments

Drug: ZD1839

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00193336

SCRI LUN 71

IRUSIRES0002

Details and patient eligibility

About

Because of the demonstrated single agent activity and excellent tolerability in patients with refractory non-small cell lung cancer, ZD1839 may be of benefit in the first-line treatment of patients with advanced non-small cell lung cancer who have poor performance status. In this phase II trial, we will investigate the single agent activity of first-line ZD1839 in patients with advanced non-small cell lung cancer with poor performance status

Full description

Upon determination of eligibility, patients will be receive:

ZD1839

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria:

Biopsy proven non-small cell lung cancer
Recurrent non-small cell lung cancer after previous surgery or radiation
Advanced disease (stage IIIb or IV)
No previous chemotherapy or biological therapy
Require significant assistance with activities of daily living
Measurable disease
Adequate bone marrow, liver and kidney function
Give written informed consent

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

Brain metastasis
Meningeal metastasis
Other uncontrolled malignancies
Women pregnant or lactating
No measurable disease outside previous radiation therapy field

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.